These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Secondary lymphedema in the mouse tail: Lymphatic hyperplasia, VEGF-C upregulation, and the protective role of MMP-9. Rutkowski JM; Moya M; Johannes J; Goldman J; Swartz MA Microvasc Res; 2006 Nov; 72(3):161-71. PubMed ID: 16876204 [TBL] [Abstract][Full Text] [Related]
45. Emerging roles of lymphatic endothelium in regulating adaptive immunity. Card CM; Yu SS; Swartz MA J Clin Invest; 2014 Mar; 124(3):943-52. PubMed ID: 24590280 [TBL] [Abstract][Full Text] [Related]
46. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269 [TBL] [Abstract][Full Text] [Related]
47. Importance of lymph vessels in the transcapillary fluid balance in the gingiva studied in a transgenic mouse model. Mkonyi LE; Bletsa A; Fristad I; Wiig H; Berggreen E Am J Physiol Heart Circ Physiol; 2010 Aug; 299(2):H275-83. PubMed ID: 20472760 [TBL] [Abstract][Full Text] [Related]
48. Lymphangiogenesis and lymphatic function in periodontal disease. Berggreen E; Wiig H J Dent Res; 2013 Dec; 92(12):1074-80. PubMed ID: 24029591 [TBL] [Abstract][Full Text] [Related]
49. Modulation of Immunity by Lymphatic Dysfunction in Lymphedema. Yuan Y; Arcucci V; Levy SM; Achen MG Front Immunol; 2019; 10():76. PubMed ID: 30761143 [TBL] [Abstract][Full Text] [Related]
50. The Kinetics of Lymphatic Dysfunction and Leukocyte Expansion in the Draining Lymph Node during LTB Cribb MT; Sestito LF; Rockson SG; Nicolls MR; Thomas SN; Dixon JB Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923272 [TBL] [Abstract][Full Text] [Related]
51. Lymph node resident rather than skin-derived dendritic cells initiate specific T cell responses after Leishmania major infection. Iezzi G; Fröhlich A; Ernst B; Ampenberger F; Saeland S; Glaichenhaus N; Kopf M J Immunol; 2006 Jul; 177(2):1250-6. PubMed ID: 16818784 [TBL] [Abstract][Full Text] [Related]
52. Inhibition of functional T cell priming and contact hypersensitivity responses by treatment with anti-secondary lymphoid chemokine antibody during hapten sensitization. Engeman TM; Gorbachev AV; Gladue RP; Heeger PS; Fairchild RL J Immunol; 2000 May; 164(10):5207-14. PubMed ID: 10799880 [TBL] [Abstract][Full Text] [Related]
53. Dermal Vγ4(+) γδ T cells possess a migratory potency to the draining lymph nodes and modulate CD8(+) T-cell activity through TNF-α production. Nakamizo S; Egawa G; Tomura M; Sakai S; Tsuchiya S; Kitoh A; Honda T; Otsuka A; Nakajima S; Dainichi T; Tanizaki H; Mitsuyama M; Sugimoto Y; Kawai K; Yoshikai Y; Miyachi Y; Kabashima K J Invest Dermatol; 2015 Apr; 135(4):1007-1015. PubMed ID: 25493651 [TBL] [Abstract][Full Text] [Related]
54. Tumor-Associated Lymphatic Vessel Features and Immunomodulatory Functions. Garnier L; Gkountidi AO; Hugues S Front Immunol; 2019; 10():720. PubMed ID: 31024552 [TBL] [Abstract][Full Text] [Related]
55. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model. Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638 [TBL] [Abstract][Full Text] [Related]
56. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. Karpanen T; Wirzenius M; Mäkinen T; Veikkola T; Haisma HJ; Achen MG; Stacker SA; Pytowski B; Ylä-Herttuala S; Alitalo K Am J Pathol; 2006 Aug; 169(2):708-18. PubMed ID: 16877368 [TBL] [Abstract][Full Text] [Related]
57. Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response. Liston A; Kohler RE; Townley S; Haylock-Jacobs S; Comerford I; Caon AC; Webster J; Harrison JM; Swann J; Clark-Lewis I; Korner H; McColl SR J Immunol; 2009 Mar; 182(5):3121-30. PubMed ID: 19234209 [TBL] [Abstract][Full Text] [Related]
58. Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation. Kimura T; Sugaya M; Oka T; Blauvelt A; Okochi H; Sato S Oncotarget; 2015 Jul; 6(20):18081-93. PubMed ID: 26098776 [TBL] [Abstract][Full Text] [Related]
59. Tumor Regulation of Lymph Node Lymphatic Sinus Growth and Lymph Flow in Mice and in Humans. Habenicht LM; Kirschbaum SB; Furuya M; Harrell MI; Ruddell A Yale J Biol Med; 2017 Sep; 90(3):403-415. PubMed ID: 28955180 [TBL] [Abstract][Full Text] [Related]
60. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. Belkaid Y; Von Stebut E; Mendez S; Lira R; Caler E; Bertholet S; Udey MC; Sacks D J Immunol; 2002 Apr; 168(8):3992-4000. PubMed ID: 11937556 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]